Ipsen: North American Head Departs, Former Novartis Executive to Take Over
Ipsen announces the appointment of Michelle C. Werner as the new Executive Vice President (EVP) and President of North America, effective March 23, 2026. She will join the Executive Leadership Team (ELT) and report directly to CEO David Loew.
Extensive Industry Experience
Michelle C. Werner comes to Ipsen from Alltrna, where she has served as President and CEO since 2022. She brings over 25 years of experience in the pharmaceutical industry. Her career includes roles at Bristol Myers Squibb (BMS), such as Director of Global Market Access Strategy for oncology and virology portfolios (2009), Global Brand Lead for the non-small cell lung carcinoma portfolio (2011), and U.S. Brand Lead for Reyataz® and Evotaz® franchises (2014). She also held positions as the Head of the Immuno-Oncology Franchise and Oncology Business Unit in the US at AstraZeneca (2015), President for the Nordic and Baltic countries based in Sweden (2018), and Global Franchise Head of Hematology (2020). Before joining Alltrna, she was the Global Franchise Head of Solid Tumors at Novartis Oncology starting in July 2020.
Leadership Transition
Keira Driansky, the former Executive Vice President and President of North America, is leaving the company to pursue external opportunities. During her two-year tenure at Ipsen, Keira Driansky led a significant transformation of the American subsidiary, contributing to increased sales in the United States and enhancing Ipsen's brand visibility in the American market.
